Overview

* Bausch + Lomb ( BLCO ) Q2 revenue of $1.278 bln beats analyst expectations

* Adjusted EPS for Q2 meets analyst estimates, per LSEG data

* Adjusted EBITDA for Q2 exceeds analyst expectations, per LSEG data

Outlook

* Bausch + Lomb ( BLCO ) raises full-year 2025 revenue guidance to $5.050 bln - $5.150 bln

* Company expects 5% - 7% constant currency revenue growth for full-year 2025

* Full-year 2025 adjusted EBITDA guidance raised to $860 mln - $910 mln

Result Drivers

* VISION CARE GROWTH - Revenue in Vision Care segment increased by 8%, driven by strong sales in dry eye portfolio and contact lenses

* SURGICAL SEGMENT CHALLENGES - Surgical segment growth of 3% was impacted by voluntary recall of enVista IOL products

* PHARMACEUTICALS DECLINE - Pharmaceuticals segment revenue decreased by 1% on a constant currency basis due to pricing pressures and decline in U.S. Generics business

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $1.28 $1.26

Revenue bln bln (11

Analysts

)

Q2 Meet $0.07 $0.07

Adjusted (12

EPS Analysts

)

Q2 EPS -$0.18

Q2 Beat $25 mln $21.80

Adjusted mln (9

Net Analysts

Income )

Q2 Net -$62 mln

Income

Q2 Beat $191 mln $187.50

Adjusted mln (10

EBITDA Analysts

)

Q2 -$11 mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Bausch + Lomb Corp ( BLCO ) is $15.50, about 5.5% above its July 29 closing price of $14.65

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)